Lupin Limited presented Phase 1 clinical trial data for LNP3693, a STING agonist, at the ESMO Congress in Berlin from October 17-21, 2025. The data provides insights into the safety and anti-tumor activity in patients with solid tumors. The presentation, titled ‘A phase 1 dose escalation study of LNP3693…’, was featured in the Investigational Immunotherapy session. This presentation is another milestone for Lupin.
Lupin Presents LNP3693 Data
Lupin Limited announced the presentation of data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany. The presentation occurred between October 17 and October 21, 2025.
Details of the Presentation
The presentation, titled “A phase 1 dose escalation study of LNP3693 (STING agonist) in patients with advanced or metastatic solid tumors & lymphoma,” was featured in the Investigational Immunotherapy session (Presentation Number 1553P). It was available for viewing on October 19, 2025, from 09:00 to 17:00 CEST.
About LNP3693
LNP3693 is an investigational parenteral STING agonist. The presentation provided qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors.
Executive Commentary
Vinita Gupta, CEO, Lupin, stated, “This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING agonist, at ESMO. ESMO’s acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development.”
ESMO Congress 2025 Details
Complete data has been provided for presentation at the ESMO Congress 2025 and addressed during the official session. All abstracts accepted for presentation were published online on October 13. They will also be published in the ESMO Congress 2025 Abstract Book.
Source: BSE
